M.D. Neranjan Tharuka

This study shows that deleting SUMO2 in CD8+ T cells enhances their activation, tumor infiltration, and anti-tumor effects by altering chromatin accessibility and gene expression.

This study shows that combining SUMO E1 inhibition with TIGIT blockade enhances anti-tumor immunity in pancreatic cancer by reducing regulatory T cells and improving T cell reactivity.

This study shows that combining SUMO inhibition with CD40 agonism enhances anti-tumor immunogenicity in PDAC by improving macrophage function and T-cell infiltration, leading to improved survival in a mouse model.